Claims
- 1. A therapeutic combination comprising a first amount of an ileal bile acid transport inhibiting compound and a second amount of a microsomal triglyceride transfer protein inhibiting compound wherein the first amount and the second amount together comprise an anti-hyperlipidemic condition effective amount, an anti-atherosclerotic condition effective amount, or an anti-hypercholesterolemic condition effective amount of the compounds.
- 2. The therapeutic combination of claim 1 wherein the ileal bile acid transport inhibitor is a compound having the structure of formula B-2:
- 3. The therapeutic combination of claim 1 wherein the ileal bile acid transport inhibiting compound has the structure of formula B-12:
- 4. The therapeutic combination of claim 1 wherein the ileal bile acid transport inhibiting compound has the structure:
- 5. The therapeutic combination of claim 1 wherein the ileal bile acid transport inhibiting compound has the structure of formula B-7:
- 6. A therapeutic combination comprising a first amount of an ileal bile acid transport inhibiting compound and a second amount of a cholesterol absorption antagonist compound wherein the first amount and the second amount together comprise an anti-hyperlipidemic condition effective amount, an anti-atherosclerotic condition effective amount, or an anti-hypercholesterolemic condition effective amount of the compounds.
- 7. The combination of claim 6 wherein the cholesterol absorption antagonist compound comprises an azetidinone compound.
- 8. The combination of claim 7 wherein the cholesterol absorption antagonist compound comprises [3R-[3α(S*),4β]]-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-2-azetidinone.
- 9. A therapeutic combination comprising a first amount of an ileal bile acid transport inhibiting compound and a second amount of an antiobesity compound wherein the first amount and the second amount together comprise an anti-hyperlipidemic condition effective amount, an anti-atherosclerotic condition effective amount, or an anti-hypercholesterolemic condition effective amount of the compounds.
- 10. The combination of claim 9 wherein the antiobesity compound comprises orlistat.
- 11. A therapeutic combination comprising a first amount of an ileal bile acid transport inhibiting compound and a second amount of an antihypertensive compound wherein the first amount and the second amount together comprise an anti-hyperlipidemic condition effective amount, an anti-atherosclerotic condition effective amount, an anti-hypercholesterolemic condition effective amount, or an antihypertensive condition effective amount of the compounds.
- 12. The combination of claim 11 wherein the ileal bile acid transport inhibiting compound comprises a benzothiazepine ileal bile acid transport inhibiting compound.
- 13. The combination of claim 12 wherein the benzothiazepine ileal bile acid transport inhibiting compound has the structure:
- 14. The combination of claim 12 wherein the benzothiazepine ileal bile acid transport inhibiting compound has the structure:
- 15. The combination of claim 11 wherein the antihypertensive compound comprises eplerenone.
- 16. The combination of claim 11 wherein the antihypertensive compound comprises spironolactone.
- 17. The combination of claim 11 wherein the antihypertensive compound comprises losartan or a salt thereof.
- 18. The combination of claim 11 wherein the ileal bile acid transport inhibiting compound comprises a benzothiepine ileal bile acid transport inhibiting compound.
- 19. The combination of claim 18 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 20. The combination of claim 18 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 21. The combination of claim 18 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 22. The combination of claim 18 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 23. The combination of claim 18 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 24. The combination of claim 18 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 25. The combination of claim 18 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 26. The combination of claim 18 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 27. The combination of claim 18 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 28. The combination of claim 18 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 29. The combination of claim 18 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 30. The combination of claim 18 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 31. The combination of claim 18 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 32. The combination of claim 18 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 33. The combination of claim 18 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 34. The combination of claim 18 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 35. The combination of claim 18 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 36. The combination of claim 18 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 37. The combination of claim 18 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 38. The combination of claim 18 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 39. The combination of claim 18 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 40. The combination of claim 18 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 41. The combination of claim 18 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 42. The combination of claim 18 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 43. The combination of claim 18 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 44. The combination of claim 18 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 45. The combination of claim 18 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 46. The combination of claim 18 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 47. The combination of claim 18 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 48. The combination of claim 18 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 49. The combination of claim 18 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 50. The combination of claim 18 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 51. The combination of claim 18 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 52. The combination of claim 18 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 53. A therapeutic combination comprising a first amount of an ileal bile acid transport inhibiting compound and a second amount of a phytosterol compound wherein the first amount and the second amount together comprise an anti-hyperlipidemic condition effective amount, an anti-atherosclerotic condition effective amount, or an anti-hypercholesterolemic condition effective amount of the compounds.
- 54. The combination of claim 54 wherein the phytosterol comprises a stanol.
- 55. The combination of claim 54 wherein the stanol is campestanol.
- 56. The combination of claim 54 wherein the stanol is cholestanol.
- 57. The combination of claim 54 wherein the stanol is clionastanol.
- 58. The combination of claim 54 wherein the stanol is coprostanol.
- 59. The combination of claim 54 wherein the stanol is 22,23-dihydrobrassicastanol.
- 60. The combination of claim 54 wherein the stanol is epicholestanol.
- 61. The combination of claim 54 wherein the stanol is fucostanol.
- 62. The combination of claim 54 wherein the stanol is stigmastanol.
- 63. The combination of claim 53 wherein the ileal bile acid transport inhibitor compound comprises a benzothiazepine ileal bile acid transport inhibitor compound.
- 64. The combination of claim 63 wherein the ileal bile acid transport inhibitor compound has the structure:
- 65. The combination of claim 63 wherein the benzothiazepine ileal bile acid transport inhibiting compound has the structure:
- 66. The combination of claim 53 wherein the ileal bile acid transport inhibiting compound comprises a benzothiepine ileal bile acid transport inhibiting compound.
- 67. The combination of claim 66 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 68. The combination of claim 66 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 69. The combination of claim 66 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 70. The combination of claim 66 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 71. The combination of claim 66 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 72. The combination of claim 66 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 73. The combination of claim 66 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 74. The combination of claim 66 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 75. The combination of claim 66 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 76. The combination of claim 66 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 77. The combination of claim 66 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 78. The combination of claim 66 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 79. The combination of claim 66 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 80. The combination of claim 66 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 81. The combination of claim 66 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 82. The combination of claim 66 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 83. The combination of claim 66 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 84. The combination of claim 66 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 85. The combination of claim 66 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 86. The combination of claim 66 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 87. The combination of claim 66 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 88. The combination of claim 66 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 89. The combination of claim 66 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 90. The combination of claim 66 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 91. The combination of claim 66 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 92. The combination of claim 66 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 93. The combination of claim 66 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 94. The combination of claim 66 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 95. The combination of claim 66 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 96. The combination of claim 66 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 97. The combination of claim 66 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 98. The combination of claim 66 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 99. The combination of claim 66 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 100. The combination of claim 66 wherein the benzothiepine ileal bile acid transport inhibiting compound has the structure:
- 101. The combination of claim 53 wherein the ileal bile acid transport inhibiting compound comprises a naphthalene ileal bile acid transport inhibiting compound.
- 102. A therapeutic combination comprising a first amount of an ileal bile acid transport inhibiting compound and a second amount of probucol wherein the first amount and the second amount together comprise an anti-hyperlipidemic condition effective amount, an anti-atherosclerotic condition effective amount, or an anti-hypercholesterolemic condition effective amount of the compounds.
- 103. The combination of claim 102 wherein the ileal bile acid transport inhibiting compound is a benzothiepine ileal bile acid transport inhibiting compound.
- 104. The combination of claim 102 wherein the ileal bile acid transport inhibiting compound is a benzothiazepine ileal bile acid transport inhibiting compound.
- 105. The combination of claim 102 wherein the ileal bile acid transport inhibiting compound is a naphthalene ileal bile acid transport inhibiting compound.
- 106. A method for the prophylaxis or treatment of a hyperlipidemic condition or disorder in a mammal which comprises administering a first amount of an ileal bile acid transport inhibitor compound and a second amount of a microsomal triglyceride transfer protein inhibiting compound wherein the first amount and the second amount together comprise an anti-hyperlipidemic condition effective amount, an anti-atherosclerotic condition effective amount, or an anti-hypercholesterolemic condition effective amount of the compounds.
- 107. A method for the prophylaxis or treatment of a hyperlipidemic condition or disorder in a mammal which comprises administering a first amount of an ileal bile acid transport inhibitor compound and a second amount of a cholesterol absorption antagonist compound wherein the first amount and the second amount together comprise an anti-hyperlipidemic condition effective amount, an anti-atherosclerotic condition effective amount, or an anti-hypercholesterolemic condition effective amount of the compounds.
- 108. A method for the prophylaxis or treatment of a hyperlipidemic condition or disorder in a mammal which comprises administering a therapeutic combination comprising a first amount of an ileal bile acid transport inhibiting compound and a second amount of an antihypertensive compound wherein the first amount and the second amount together comprise an anti-hyperlipidemic condition effective amount of the compounds.
- 109. A method for the prophylaxis or treatment of a hyperlipidemic condition or disorder in a mammal which comprises administering a first amount of an ileal bile acid transport inhibitor compound and a second amount of a phytosterol compound wherein the first amount and the second amount together comprise an anti-hyperlipidemic condition effective amount, an anti-atherosclerotic condition effective amount, or an anti-hypercholesterolemic condition effective amount of the compounds.
- 110. The method of claim 110 wherein the phytosterol compound comprises a stanol.
- 111. A kit for achieving a therapeutic effect in a mammal comprising an amount of an ileal bile acid transport inhibiting compound in a first unit dosage form; an amount of a microsomal triglyceride transfer protein inhibiting compound in a second unit dosage form; and container means for containing said first and second unit dosage forms.
- 112. A kit for achieving a therapeutic effect in a mammal comprising an amount of an ileal bile acid transport inhibiting compound in a first unit dosage form; an amount of a cholesterol absorption antagonist compound in a second unit dosage form; and container means for containing said first and second unit dosage forms.
- 113. A kit for achieving a therapeutic effect in a mammal comprising an amount of an ileal bile acid transport inhibiting compound in a first unit dosage form; an amount of an antihypertensive compound in a second unit dosage form; and container means for containing said first and second unit dosage forms.
- 114. A kit for achieving a therapeutic effect in a mammal comprising an amount of an ileal bile acid transport inhibiting compound in a first unit dosage form; an amount of a phytosterol compound in a second unit dosage form; and container means for containing said first and second unit dosage forms.
- 115. The kit of claim 114 wherein the phytosterol compound comprises a stanol.
Parent Case Info
[0001] This application claims priority of U.S. provisional application Ser. No. 60/113,955 filed Dec. 23, 1998.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60113955 |
Dec 1998 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
09466596 |
Dec 1999 |
US |
Child |
10266743 |
Oct 2002 |
US |